Luca Schierbaum,Vicente Quiroz,Kathryn Yang,Joshua Rong,Nicole Battaglia,Umar Zubair,Michelle R. Christie,Marie Y. Davis,Daniel G. Calame,Matt C. Danzi,Richard S. Finkel,Joshua Burns,Donald L. Gilbert,Dararat Mingbunjerdsuk,Greg Pruitt,Norma Pruitt,John Cobb,Reza Sadjadi,Christopher R. Cashman,Craig Blackstone
The primary objective of this paper was to present the establishment of the Spastic Paraplegia-Centers of Excellence Research Network (SP-CERN) aimed at promoting clinical trial readiness for hereditary spastic paraplegia (HSP). SP-CERN is unique in its approach to addressing the diagnostic and therapeutic challenges associated with HSP through a large-scale, collaborative effort. Participants with HSP are identified through multicenter collaborations across 11 institutions in the United States. SP-CERN systematically collects longitudinal clinical data, biospecimens, and wearable device data from patients. Data are stored in a centralized REDCap database, facilitating shared access for analysis. Patients are evaluated using standardized assessment tools for motor function, biomarkers, and digital outcome measures. SP-CERN has established a biorepository, centralized data collection methods, and standardized clinical assessments. It is conducting natural history studies for all HSP subtypes, enabling the validation of biomarkers and development of gene-based therapies. SP-CERN's collaborative approach bridges gaps in clinical care and research for HSP by improving diagnostic capabilities and promoting clinical trial readiness. This initiative represents a framework for rare disease research, accelerating the development of novel therapies and improving patient outcomes through standardized, multi-institutional collaboration.